Prices delayed by at least 15 minutes | Print
CASI Pharmaceuticals (CASI)
Ordinary SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Address
9620 Medical Center Drive
Suite 300
Rockville
MD
USA
20850
Telephone
+1 240 8642643
Forecast key dates
| Name | Key Date |
|---|---|
| CASI Pharmaceuticals Inc First Quarter Earnings Results for 2025 | 2025-05-20T00:00:00 |
| CASI Pharmaceuticals Inc Fourth Quarter Earnings Results for 2024 | 2025-03-28T00:00:00 |
| CASI Pharmaceuticals Inc Annual Report for 2024 | 2025-03-28T00:00:00 |
| CASI Pharmaceuticals Inc Third Quarter Earnings Results for 2024 | 2024-11-01T00:00:00 |
| CASI Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2024 | 2024-08-20T00:00:00 |
| CASI Pharmaceuticals Inc Second Quarter Earnings Result for 2024 | 2024-08-20T00:00:00 |
| CASI Pharmaceuticals Inc First Quarter Earnings Results for 2024 | 2024-05-20T00:00:00 |
| CASI Pharmaceuticals Inc Annual General Meeting for 2023 | 2024-05-15T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| CASI Pharmaceuticals Inc First Quarter Earnings Results for 2024 | 2024-05-20T00:00:00 |
| CASI Pharmaceuticals Inc Annual General Meeting for 2023 | 2024-05-15T00:00:00 |
| CASI Pharmaceuticals Inc Fourth Quarter Earnings Results for 2023 | 2024-03-28T00:00:00 |
| CASI Pharmaceuticals Inc Annual Report for 2023 | 2024-03-28T00:00:00 |
| CASI Pharmaceuticals Inc Third Quarter Earnings Results for 2023 | 2023-11-01T00:00:00 |
| CASI Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2023 | 2023-08-01T00:00:00 |
| CASI Pharmaceuticals Inc Second Quarter Earnings Result for 2023 | 2023-08-01T00:00:00 |
| CASI Pharmaceuticals Inc First Quarter Earnings Results for 2023 | 2023-05-17T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.